Sequence: SHGRITFAYFAN
| Experiment Id | EXP002492 |
|---|---|
| Paper | Delivery System Targeting Hemagglutinin of Influenza Virus A to Facilitate Antisense-Based Anti-H1N1 |
| Peptide | HA-binding peptide HABP / H17 |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 14.4 mg/kg/day intranasal in survival study; 0.58, 2.88, or 14.4 mg/kg tested for M1 vRNA dose response |
| Mixing Ratio | |
| Formulation Format | Covalent peptide-ODN conjugate |
| Formulation Components | HABP peptide + anti-IAV flutide ODN via EMCS linker |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c mice infected intranasally with A/FM/1/47 (H1N1) |
| Administration Route | Intranasal |
| Output Type | In vivo antiviral efficacy / survival / viral RNA reduction / lung delivery |
| Output Value | Protected 80% of mice from lethal challenge; reduced M1 vRNA dose-dependently; enhanced lung fluorescence delivery (~2.4-fold over ODN/control at 4 h); reduced weight loss similar to zanamivir |
| Output Units | |
| Output Notes | Functional in vivo antiviral effect and viral RNA reduction justify delivery_success_class=1. Uptake confirmed by lung fluorescence and immunostaining in infected mice. |
| Toxicity Notes | No detailed toxicity findings reported in the main article; survival and body weight tracked. |
| Curation Notes |